The 9 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 10.00, with a high estimate of 14.00 and a low estimate of 8.00. The median estimate represents a +154.45% increase from the last price of 3.93.
The current consensus among 9 polled investment analysts is to Buy stock in Cymabay Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.26
Reporting Date Mar 16
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.